Top

Published in:

01-10-2008 | Review

Developments in the scientific and clinical understanding of inflammatory myopathies

Authors: Ingrid E Lundberg, Cecilia Grundtman

Published in: Arthritis Research & Therapy | Issue 5/2008

Abstract

The idiopathic inflammatory myopathies are chronic autoimmune disorders sharing the clinical symptom of muscle weakness and, in typical cases, inflammatory cell infiltrates in muscle tissue. During the last decade, novel information has accumulated supporting a role of both the innate and adaptive immune systems in myositis and suggesting that different molecular pathways predominate in different subsets of myositis. The type I interferon activity is one such novel pathway identified in some subsets of myositis. Furthermore, nonimmunological pathways have been identified, suggesting that factors other than direct T cell-mediated muscle fibre necrosis could have a role in the development of muscle weakness.

Available only for authorised users

Arahata K, Engel AG: Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 1984, 16: 193-208. 10.1002/ana.410160206.CrossRefPubMed

Englund P, Wahlström J, Fathi M, Rasmussen E, Grunewald J, Tornling G, Lundberg IE: Restricted T cell receptor BV gene usage in the lungs and muscles of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 2007, 56: 372-383. 10.1002/art.22293.CrossRefPubMed

Lindberg C, Oldfors A, Tarkowski A: Local T-cell proliferation and differentiation in inflammatory myopathies. Scand J Immunol. 1995, 41: 421-426. 10.1111/j.1365-3083.1995.tb03587.x.CrossRefPubMed

Greenberg SA, Bradshaw EM, Pinkus JL, Pinkus GS, Burleson T, Due B, Bregoli L, O'Connor KC, Amato AA: Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology. 2005, 65: 1782-1787. 10.1212/01.wnl.0000187124.92826.20.CrossRefPubMed

Arahata K, Engel AG: Monoclonal antibody analysis of mononuclear cells in myopathies. III: Immunoelectron microscopy aspects of cell-mediated muscle fiber injury. Ann Neurol. 1986, 19: 112-125. 10.1002/ana.410190203.CrossRefPubMed

Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, Pongratz D, Johnson MA, Wekerle H, Tschopp J, Jenne D, Hohlfeld R: Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest. 1996, 97: 2905-2910. 10.1172/JCI118749.PubMedCentralCrossRefPubMed

Salajegheh M, Rakocevic G, Raju R, Shatunov A, Goldfarb LG, Dalakas MC: T cell receptor profiling in muscle and blood lymphocytes in sporadic inclusion body myositis. Neurology. 2007, 69: 1672-1679. 10.1212/01.wnl.0000265398.77681.09.CrossRefPubMed

Yamada A, Kishimoto K, Dong VM, Sho M, Salama AD, Anosova NG, Benichou G, Mandelbrot DA, Sharpe AH, Turka LA, Auchincloss H, Sayegh MH: CD28-independent costimulation of T cells in alloimmune responses. J Immunol. 2001, 167: 140-146.CrossRefPubMed

Lundberg I, Kratz AK, Alexanderson H, Patarroyo M: Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum. 2000, 43: 336-348. 10.1002/1529-0131(200002)43:2<336::AID-ANR13>3.0.CO;2-V.CrossRefPubMed

10.

Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG: Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med. 1980, 92: 365-369.CrossRefPubMed

11.

Korotkova M, Barbasso Helmers S, Loell I, Alexanderson H, Grundtman C, Dorph C, Lundberg IE, Jakobsson PJ: Effects of immunosuppressive treatment on microsomal PGE synthase 1 and cyclooxygenases expression in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis. 2007 Dec 18., [Epub ahead of print].

12.

Fasth AE, Snir O, Johansson AA, Nordmark B, Rahbar A, Af Klint E, Björkström NK, Ulfgren AK, van Vollenhoven RF, Malmström V, Trollmo C: Skewed distribution of proinflammatory CD4⁺CD28^null T cells in rheumatoid arthritis. Arthritis Res Ther. 2007, 9: R87-10.1186/ar2286.PubMedCentralCrossRefPubMed

13.

Fasth AER, Rahbar A, Dastmalchi M, Söderberg-Nauclér C, Trollmo C, Lundberg IE, Malmström V: Human cytomegalovirus: a possible activator of the immune system in polymyositis and dermatomyositis. Am Coll Rheumatol. 2007, Poster 1671.

14.

Hagiwara E, Adams EM, Plotz PH, Klinman DM: Abnormal numbers of cytokine producing cells in patients with polymyositis and dermatomyositis. Clin Exp Rheumatol. 1996, 14: 485-491.PubMed

15.

Lundberg I, Brengman JM, Engel AG: Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol. 1995, 63: 9-16. 10.1016/0165-5728(95)00122-0.CrossRefPubMed

16.

Lundberg I, Ulfgren AK, Nyberg P, Andersson U, Klareskog L: Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997, 40: 865-874. 10.1002/art.1780400514.CrossRefPubMed

17.

Salomonsson S, Lundberg IE: Cytokines in idiopathic inflammatory myopathies. Autoimmunity. 2006, 39: 177-190. 10.1080/08916930600622256.CrossRefPubMed

18.

Greenberg SA, Sanoudou D, Haslett JN, Kohane IS, Kunkel LM, Beggs AH, Amato AA: Molecular profiles of inflammatory myopathies. Neurology. 2002, 59: 1170-1182.CrossRefPubMed

19.

Lepidi H, Frances V, Figarella-Branger D, Bartoli C, Machado-Baeta A, Pellissier JF: Local expression of cytokines in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol. 1998, 24: 73-79. 10.1046/j.1365-2990.1998.00092.x.CrossRefPubMed

20.

Page G, Chevrel G, Miossec P: Anatomic localization of immature and mature dendritic cell subsets in dermatomyositis and polymyositis: interaction with chemokines and Th1 cytokine-producing cells. Arthritis Rheum. 2004, 50: 199-208. 10.1002/art.11428.CrossRefPubMed

21.

Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P: Interleukin-17 increases the effects of IL-1 beta on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol. 2003, 137: 125-133. 10.1016/S0165-5728(03)00032-8.CrossRefPubMed

22.

Greenberg SA, Pinkus GS, Amato AA, Pinkus JL: Myeloid den-dritic cells in inclusion-body myositis and polymyositis. Muscle Nerve. 2007, 35: 17-23. 10.1002/mus.20649.CrossRefPubMed

23.

Nagaraju K, Rider LG, Fan C, Chen YW, Mitsak M, Rawat R, Patterson K, Grundtman C, Miller FW, Plotz PH, Hoffman E, Lundberg IE: Endothelial cell activation and neovascularization are prominent in dermatomyositis. J Autoimmune Dis. 2006, 3: 2-10.1186/1740-2557-3-2.PubMedCentralCrossRefPubMed

24.

Eloranta ML, Barbasso Helmers S, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE: A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007, 56: 3112-3124. 10.1002/art.22860.CrossRefPubMed

25.

Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, Tawil R, Barohn RJ, Saperstein DS, Briemberg HR, Ericsson M, Park P, Amato AA: Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol. 2005, 57: 664-678. 10.1002/ana.20464.CrossRefPubMed

26.

McNiff JM, Kaplan DH: Plasmacytoid dendritic cells are present in cutaneous dermatomyositis lesions in a pattern distinct from lupus erythematosus. J Cutan Pathol. 2008, 35: 452-456. 10.1111/j.1600-0560.2007.00848.x.CrossRefPubMed

27.

Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, Ytterberg SR, Gregersen PK, Behrens TW, Reed AM: An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med. 2007, 13: 59-68. 10.2119/2006-00085.Baechler.PubMedCentralCrossRefPubMed

28.

Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, Beggs AH, Amato AA, Greenberg SA: Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum. 2007, 56: 3784-3792. 10.1002/art.22928.PubMedCentralCrossRefPubMed

29.

Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Barbasso Helmers S, Elvin K, Crow MK, Nennesmo I, Lundberg IE: A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008 Feb 13 [Epub ahead of print].

30.

Mavragani CP, Niewold TB, Moutsopoulos NM, Pillemer SR, Wahl SM, Crow MK: Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum. 2007, 56: 3995-4004. 10.1002/art.23062.PubMedCentralCrossRefPubMed

31.

Englund P, Nennesmo I, Klareskog L, Lundberg IE: Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum. 2002, 46: 1044-1055. 10.1002/art.10140.CrossRefPubMed

32.

Nyberg P, Wikman AL, Nennesmo I, Lundberg I: Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol. 2000, 27: 940-948.PubMed

33.

Grundtman C, Salomonsson S, Dorph C, Bruton J, Andersson U, Lundberg IE: Immunolocalization of interleukin-1 receptors in the sarcolemma and nuclei of skeletal muscle in patients with idiopathic inflammatory myopathies. Arthritis Rheum. 2007, 56: 674-687. 10.1002/art.22388.CrossRefPubMed

34.

Reid MB, Lannergren J, Westerblad H: Respiratory and limb muscle weakness induced by tumor necrosis factor-alpha: involvement of muscle myofilaments. Am J Respir Crit Care Med. 2002, 166: 479-484. 10.1164/rccm.2202005.CrossRefPubMed

35.

Furlan A, Botsios C, Ruffatti A, Todesco S, Punzi L: Antisynthetase syndrome with refractory polyarthritis and fever successfully treated with the IL-1 receptor antagonist, anakinra: a case report. Joint Bone Spine. 2008, 75: 366-367. 10.1016/j.jbspin.2007.07.010.CrossRefPubMed

36.

Tucci M, Quatraro C, Dammacco F, Silvestris F: Interleukin-18 overexpression as a hallmark of the activity of autoimmune inflammatory myopathies. Clin Exp Immunol. 2006, 146: 21-31. 10.1111/j.1365-2249.2006.03180.x.PubMedCentralCrossRefPubMed

37.

Efthimiou P, Schwartzman S, Kagen LJ: Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis. 2006, 65: 1233-1236. 10.1136/ard.2005.048744.PubMedCentralCrossRefPubMed

38.

Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, Janson A, Kokkola R, Zhang M, Yang H, Tracey KJ: High mobility group 1 protein (HMG-1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med. 2000, 192: 565-570. 10.1084/jem.192.4.565.PubMedCentralCrossRefPubMed

39.

Ulfgren AK, Grundtman C, Borg K, Alexanderson H, Andersson U, Harris HE, Lundberg IE: Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum. 2004, 50: 1586-1594. 10.1002/art.20220.CrossRefPubMed

40.

Miller FW, Waite KA, Biswas T, Plotz PH: The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci USA. 1990, 87: 9933-9937. 10.1073/pnas.87.24.9933.PubMedCentralCrossRefPubMed

41.

Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, Domsic R, Ascherman DP: Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007, 56: 3125-3131. 10.1002/art.22865.CrossRefPubMed

42.

Miller FW, Twitty SA, Biswas T, Plotz PH: Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. J Clin Invest. 1990, 85: 468-475. 10.1172/JCI114461.PubMedCentralCrossRefPubMed

43.

Krystufkova O, Vallerskog T, Barbasso Helmers S, Mann H, Pùtová I, Belácek J, Malmström V, Trollmo C, Vencovsky J, Lundberg IE: Increased serum levels of B-cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis. 2008 Jul 15 [Epub ahead of print].

44.

Bradshaw EM, Orihuela A, McArdel SL, Salajegheh M, Amato AA, Hafler DA, Greenberg SA, O'Connor KC: A local antigen-driven humoral response is present in the inflammatory myopathies. J Immunol. 2007, 178: 547-556.CrossRefPubMed

45.

Martin A, Shulman MJ, Tsui FW: Epitope studies indicate that histidyl-tRNA synthetase is a stimulating antigen in idiopathic myositis. FASEB J. 1995, 9: 1226-1233.PubMed

46.

Raben N, Nichols R, Dohlman J, McPhie P, Sridhar V, Hyde C, Leff R, Plotz P: A motif in human histidyl-tRNA synthetase which is shared among several aminoacyl-tRNA synthetases is a coiled-coil that is essential for enzymatic activity and contains the major autoantigenic epitope. J Biol Chem. 1994, 269: 24277-24283.PubMed

47.

Lovgren T, Eloranta ML, Kastner B, Wahren-Herlenius M, Alm GV, Ronnblom L: Induction of interferon-alpha by immune complexes or liposomes containing systemic lupus erythematosus autoantigen- and Sjogren's syndrome autoantigen-associated RNA. Arthritis Rheum. 2006, 54: 1917-1927. 10.1002/art.21893.CrossRefPubMed

48.

Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW: A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore). 1991, 70: 360-374.CrossRef

49.

Marguerie C, Bunn CC, Beynon HL, Bernstein RM, Hughes JM, So AK, Walport MJ: Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. Q J Med. 1990, 77: 1019-1038.CrossRefPubMed

50.

Levine SM, Raben N, Xie D, Askin FB, Tuder R, Mullins M, Rosen A, Casciola-Rosen LA: Novel conformation of histidyltransfer RNA synthetase in the lung: the target tissue in Jo-1 autoanti-body-associated myositis. Arthritis Rheum. 2007, 56: 2729-2739. 10.1002/art.22790.CrossRefPubMed

51.

Katsumata Y, Ridgway WM, Oriss T, Gu X, Chin D, Wu Y, Fertig N, Oury T, Vandersteen D, Clemens P, Camacho CJ, Weinberg A, Ascherman DP: Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun. 2007, 29: 174-186. 10.1016/j.jaut.2007.07.005.PubMedCentralCrossRefPubMed

52.

Casciola-Rosen L, Nagaraju K, Plotz P, Wang K, Levine S, Gabrielson E, Corse A, Rosen A: Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med. 2005, 201: 591-601. 10.1084/jem.20041367.PubMedCentralCrossRefPubMed

53.

Brouwer R, Hengstman GJ, Vree Egberts W, Ehrfeld H, Bozic B, Ghirardello A, Grøndal G, Hietarinta M, Isenberg D, Kalden JR, Lundberg I, Moutsopoulos H, Roux-Lombard P, Vencovsky J, Wikman A, Seelig HP, van Engelen BG, van Venrooij WJ: Autoantibody profiles in the sera of European patients with myositis. Ann Rheum Dis. 2001, 60: 116-123. 10.1136/ard.60.2.116.PubMedCentralCrossRefPubMed

54.

Hengstman GJ, Vree Egberts WT, Seelig HP, Lundberg IE, Moutsopoulos HM, Doria A, Mosca M, Vencovsky J, van Venrooij WJ, van Engelen BG: Clinical characteristics of patients with myositis and autoantibodies to different fragments of the Mi-2 beta antigen. Ann Rheum Dis. 2006, 65: 242-245. 10.1136/ard.2005.040717.PubMedCentralCrossRefPubMed

55.

Targoff IN, Mamyrova G, Trieu EP, Perurena O, Koneru B, O'Hanlon TP, Miller FW, Rider LG, Childhood Myositis Heterogeneity Study Group; International Myositis Collaborative Study Group: A novel autoantibody to a 155-kd protein is associated with dermatomyositis. Arthritis Rheum. 2006, 54: 3682-3689. 10.1002/art.22164.CrossRefPubMed

56.

Nagaraju K, Casciola-Rosen L, Lundberg I, Rawat R, Cutting S, Thapliyal R, Chang J, Dwivedi S, Mitsak M, Chen YW, Plotz P, Rosen A, Hoffman E, Raben N: Activation of the endoplasmic reticulum stress response in autoimmune myositis: potential role in muscle fiber damage and dysfunction. Arthritis Rheum. 2005, 52: 1824-1835. 10.1002/art.21103.CrossRefPubMed

57.

Emslie-Smith AM, Engel AG: Microvascular changes in early and advanced dermatomyositis: a quantitative study. Ann Neurol. 1990, 27: 343-356. 10.1002/ana.410270402.CrossRefPubMed

58.

Kissel JT, Mendell JR, Rammohan KW: Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med. 1986, 314: 329-334.CrossRefPubMed

59.

Girard JP, Springer TA: High endothelial venules (HEVs): specialized endothelium for lymphocyte migration. Immunol Today. 1995, 16: 449-457. 10.1016/0167-5699(95)80023-9.CrossRefPubMed

60.

Grundtman C, Tham E, Ulfgren A-K, Lundberg IE: Vascular endothelium growth factor is highly expressed in muscle tissue of patients with polymyositis and patients with dermatomyositis. Arthritis Rheum. 2008 58: in press.

61.

Karpati G, Pouliot Y, Carpenter S: Expression of immunoreactive major histocompatibility complex products in human skeletal muscles. Ann Neurol. 1988, 23: 64-72. 10.1002/ana.410230111.CrossRefPubMed

62.

Civatte M, Schleinitz N, Krammer P, Fernandez C, Guis S, Veit V, Pouget J, Harlé JR, Pellissier JF, Figarella-Branger D: Class I MHC detection as a diagnostic tool in noninformative muscle biopsies of patients suffering from dermatomyositis (DM). Neuropathol Appl Neurobiol. 2003, 29: 546-552. 10.1046/j.1365-2990.2003.00471.x.CrossRefPubMed

63.

Nagaraju K, Raben N, Villalba ML, Danning C, Loeffler LA, Lee E, Tresser N, Abati A, Fetsch P, Plotz PH: Costimulatory markers in muscle of patients with idiopathic inflammatory myopathies and in cultured muscle cells. Clin Immunol. 1999, 92: 161-169. 10.1006/clim.1999.4743.CrossRefPubMed

64.

Pavlath GK: Regulation of class I MHC expression in skeletal muscle: deleterious effect of aberrant expression on myogenesis. J Neuroimmunol. 2002, 125: 42-50. 10.1016/S0165-5728(02)00026-7.CrossRefPubMed

65.

Nagaraju K, Raben N, Loeffler L, Parker T, Rochon PJ, Lee E, Danning C, Wada R, Thompson C, Bahtiyar G, Craft J, Hooft Van Huijsduijnen R, Plotz P: Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci USA. 2000, 97: 9209-9214. 10.1073/pnas.97.16.9209.PubMedCentralCrossRefPubMed

66.

Salomonsson S, Grundtman C, Zhang S-J, Lanner JT, Li C, Katz A, Wedderburn LR, Nagaraju K, Lundberg IE, Westerblad H: Up-regulation of MHC class I in tansgenic mice results in reduced force-generating capacity in slow-twitch muscle. Muscle Nerve. 2008, in press

67.

Dastmalchi M, Alexanderson H, Loell I, Ståhlberg M, Borg K, Lundberg IE, Esbjörnsson M: Effect of physical training on the proportion of slowtwitch type I muscle fibers, a novel nonimmune-mediated mechanism for muscle impairment in polymyositis or dermatomyositis. Arthritis Rheum. 2007, 57: 1303-1310. 10.1002/art.22996.CrossRefPubMed

68.

Chung YL, Alexanderson H, Pipitone N, Morrison C, Dastmalchi M, Ståhl-Hallengren C, Richards S, Thomas EL, Hamilton G, Bell JD, Lundberg IE, Scott DL: Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007, 57: 694-702. 10.1002/art.22687.CrossRefPubMed

Title: Developments in the scientific and clinical understanding of inflammatory myopathies
Authors: Ingrid E Lundberg
Cecilia Grundtman
Publication date: 01-10-2008
Publisher: BioMed Central
Published in: Arthritis Research & Therapy / Issue 5/2008
Electronic ISSN: 1478-6362
DOI: https://doi.org/10.1186/ar2501

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2008

Mesenchymal stem cells in arthritic diseases

Developments in the scientific understanding of lupus

Virally associated arthritis 2008: clinical, epidemiologic, and pathophysiologic considerations

Lipooxygenase inhibition in osteoarthritis: a potential symptomatic and disease modifying effect?

Toll-like receptor homolog RP105 modulates the antigen-presenting cell function and regulates the development of collagen-induced arthritis

Immune regulation of bone loss by Th17 cells

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials